NCT06737016 Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.
| NCT ID | NCT06737016 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Mansoura University |
| Condition | Posterior Urethral Valve |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 50 participants in total. It began in 2024-11-01 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine whether there is a role for Tamsulosin, A Selective Alpha-1 Adrenergic Blocker, as therapy in children with Posterior Urethral Valve post valve ablation , and whether there are side effects involved.
Eligibility Criteria
Inclusion Criteria: * Children with a diagnosis of PUV. Exclusion Criteria: 1. Patients with other conditions that can potentially affect lower or upper urinary tract functions (e.g. spinal dysraphism, anorectal malformation and prune belly syndrome) 2. Patients who were treated with urinary diversion as vesicostomy or cutaneous ureterostomy. 3. Patients who had primary treatment of PUV ablation at other hospitals. 4. Contraindications to α blocker treatment. 5. Patients who refuse to participate in the study
Contact & Investigator
Ashraf Tarek Hafez
STUDY CHAIR
urology and nephrology center mansoura university
Frequently Asked Questions
Who can join the NCT06737016 clinical trial?
This trial is open to male participants only, up to 12 Years, studying Posterior Urethral Valve. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06737016 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 50 participants.
Is NCT06737016 currently recruiting?
Yes, NCT06737016 is actively recruiting participants. Contact the research team at mohamedhussiny1@yahoo.com for enrollment information.
Where is the NCT06737016 trial being conducted?
This trial is being conducted at Al Mansurah, Egypt.
Who is sponsoring the NCT06737016 clinical trial?
NCT06737016 is sponsored by Mansoura University. The principal investigator is Ashraf Tarek Hafez at urology and nephrology center mansoura university. The trial plans to enroll 50 participants.